TrialNature communications2026

Cadonilimab plus chemotherapy as first-line treatment in PD-L1-negative advanced non-small cell lung cancer: a phase II clinical trial.

Li Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.